Linda Metheny-Barlow Lab

Metheny-Barlow Lab


Linda Metheny-Barlow Lab

From left to right:  Valerie Payne, Christine Naczki, Linda Metheny-Barlow, Wenhong Chen and Mitra Kooshki

Regulation of Vascular Integrity and Metastasis
My long-term research interests include the regulation of angiogenesis and the role of vascular mural cells (pericytes and smooth muscle cells) in the breast tumor microenvironment.  My previous work has demonstrated that mural cells can respond directly to angiopoietin-1 to help stabilize the breast tumor vasculature.  More recently, we have used in vitro co-culture models to analyze paracrine interactions between mural cells, endothelial cells, and breast cancer cells in order to identify critical tumor-induced alterations in mural cell function that may contribute to the maturation defect exhibited by the tumor vasculature.  We have determined that functional gap junction protein Connexin 43 (Cx43) is required for proper stabilizing interactions between mural cells and endothelial cells, and that tumor cells downregulate or inactivate mural cell Cx43 to elicit endothelial proliferation in co-cultures.  Furthermore, tumor angiogenesis proceeds more rapidly on a Cx43-deficient host background, with decreased pericyte investiture of tumor vessels.  Of particular interest, this decreased vessel stabilization is associated with an increase in metastasis to the lung in the Cx43-deficient host.  Our ongoing studies seek to better define the factors leading to Cx43 dysregulation in tumor vessels, and the role of mural/vascular cell Cx43 in inhibition of metastasis.

Molecular Determinants of Breast Cancer Metastasis to Brain
A second major interest in my lab is the development and characterization of models to study breast cancer brain metastasis development and treatment, with a focus on tumor-brain microenvironment interactions.  We have developed two syngeneic rodent models of breast cancer brain metastasis which we are using to identify potential targets for therapeutic intervention, as well as to assess their effects on the brain vasculature and interactions with microglia.  Our current efforts are addressed at defining the role of autocrine and paracrine brain derived neurotrophic factor (BDNF)-p75NTR signaling in breast cancer metastasis to the brain, and the testing of therapeutics to mitigate this signaling to prevent or treat brain metastases.   

Radiation Modifiers for Brain Metastasis:  Effects on Tumor Response, Brain Injury and Cognition
Since radiation therapy is the primary modality for treatment of brain metastases, we have extended our studies to include the therapeutic tumor and normal tissue responses to radiation. Although fractionated whole brain irradiation (fWBI) can be successfully used to achieve tumor control of brain metastatic disease, patients surviving longer than six months are frequently afflicted with a progressive, irreversible cognitive impairment resulting from the therapy.  We seek to better define the mechanisms by which radiation injures the normal brain, and identify compounds that can mitigate radiation-induced normal brain injury without adversely impacting therapeutic response to the tumor.  We are currently investigating the use of cognition-sparing Peroxisomal Proliferator-Activated Receptor (PPAR) agonists to i) mitigate radiation-induced activation of microglia and astrocytes; ii) prevent radiation-induced alterations of glutamatergic signaling; and iii) inhibit growth of brain metastatic cells, with or without radiation.   


Quick Reference

Radiation Oncology Research



Find A Doctor Ways to Give
Last Updated: 07-16-2015
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.